Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cassava Sciences Inc
(NQ:
SAVA
)
9.331
-4.199 (-31.04%)
Streaming Delayed Price
Updated: 12:10 PM EDT, Jul 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cassava Sciences Inc
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
31
32
Next >
CASSAVA SCIENCES INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Cassava Sciences, Inc. - SAVA
July 15, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
June 29, 2022
Palm Beach, FL – June 29 2022 – FinancialNewsMedia.com News Commentary – In the central nervous system (CNS) therapeutics market, large and small pharmaceutical companies are highly investing in the...
Via
FinancialNewsMedia
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
June 15, 2022
Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited.
Via
Benzinga
Recap: Cassava Sciences Q1 Earnings
May 05, 2022
Cassava Sciences (NASDAQ:SAVA) reported its Q1 earnings results on Thursday, May 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Cassava Sciences May Be Heading Below $10 Per Share
May 04, 2022
Cassava Sciences is facing criticism around its lead drug candidate. If that drug doesn't work, SAVA stock has a lot farther left to fall.
Via
InvestorPlace
5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise
June 06, 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.
Via
Benzinga
Cassava Sciences, Inc. (NASDAQ:SAVA) Investor Alert: Investigation over Possible Violations of Securities Laws
June 02, 2022
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Cassava Sciences, Inc is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
12 Health Care Stocks Moving In Tuesday's Intraday Session
May 31, 2022
Via
Benzinga
The 7 Best Meme Stocks to Buy Now
May 25, 2022
The meme stock craze might never be what it was last year, but these meme stocks to buy that are still worth another look.
Via
InvestorPlace
5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List
May 24, 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.
Via
Benzinga
Why Is Cassava Sciences (SAVA) Stock Down Today?
April 19, 2022
SAVA stock is tumbling after The New York Times reported that multiple experts are skeptical about Cassava's data and its main theory.
Via
InvestorPlace
Global Psychedelics Market Is Expected To Reach $8 Billion By 2029
May 24, 2022
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster...
Via
FinancialNewsMedia
Short Squeeze Stocks: BBAI, MMAT and 3 Others Experts Think Are Ready to Pop
May 23, 2022
Short squeeze stocks continue to be of interest to retail traders looking to pump up shares while pushing hedge funds out of a company.
Via
InvestorPlace
How Is The Market Feeling About Cassava Sciences?
May 12, 2022
Cassava Sciences's (NASDAQ:SAVA) short percent of float has risen 7.39% since its last report. The company recently reported that it has 11.46 million shares sold short, which is...
Via
Benzinga
What Are Whales Doing With Cassava Sciences
May 04, 2022
Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly...
Via
Benzinga
Here's How Much You Would Have Made Owning Cassava Sciences Stock In The Last 5 Years
May 03, 2022
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 25.46% on an annualized basis producing an average annual return of 37.25%. Currently, Cassava Sciences has a market...
Via
Benzinga
Stay Far Away From Cassava Sciences Amid Data Integrity Criticisms
April 29, 2022
Serious allegations have been made against Cassava by multiple sources, making SAVA stock far too risky for investors at this point.
Via
InvestorPlace
Take Full Advantage of Weakness in Cassava Sciences Stock
April 26, 2022
Cassava could run back to $40 again. Should the company get a positive nod for its Alzheimer’s treatment, it could see $140 again.
Via
InvestorPlace
Cassava Sciences Is a Worthwhile Bet to Consider
April 25, 2022
FDA approval for Simufilam and successful trials of a new blood test to detect Alzheimer's disease could help propel SAVA stock back up.
Via
InvestorPlace
CASSAVA ALERT: Bragar Eagel & Squire, P.C. is Investigating Cassava Sciences, Inc. on Behalf of Cassava Stockholders and Encourages Investors to Contact the Firm
April 21, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
The Crowd Has Wisely Soured on Cassava Sciences Stock
April 20, 2022
Recent headlines suggest Simulfilam has a slim chance of obtaining FDA approval, justifying the move of SAVA stock to lower prices.
Via
InvestorPlace
54 Biggest Movers From Yesterday
April 20, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) shares jumped 325.9% to close at $10.35 on Tuesday after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
April 19, 2022
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) stock increased by 331.9% to $10.41 during Tuesday's regular session. Trading volume for Checkmate Pharmaceuticals'...
Via
Benzinga
$1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth This Much
April 19, 2022
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 19.11% on an annualized basis producing an average annual return of 32.41%. Currently, Cassava Sciences has a market...
Via
Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
April 19, 2022
Gainers Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) climbed 329.2% to $10.43 after Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced a deal to acquire the company for $...
Via
Benzinga
Why Is ToughBuilt Industries (TBLT) Stock Up 65% Today?
April 19, 2022
ToughBuilt Industries (TBLT) stock is rocketing higher Tuesday following the release of the company's Q4 2021 earnings report.
Via
InvestorPlace
Why Is Johnson & Johnson (JNJ) Stock in Focus Today?
April 19, 2022
Johnson & Johnson (JNJ) stock is on the move Tuesday as investors react to the company's earnings report for the first quarter of 2022.
Via
InvestorPlace
Stocks That Hit 52-Week Lows On Tuesday
April 19, 2022
On Tuesday, 242 companies hit new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was...
Via
Benzinga
New York Times Report Fresh Allegations On Cassava's Simufilam Alzheimer's Trials, Shares Fall
April 19, 2022
Cassava Sciences Inc (NASDAQ: SAVA) shares are shedding over 20% after
Via
Benzinga
Benzinga's Daily Brief On Trending Tickers For April 19, 2022: Plug Power, Twitter, Cassava Sciences And More
April 19, 2022
Benzinga’s “Daily Brief On Trending Tickers” features top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items...
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.